Status:
COMPLETED
Pathomolecular Analysis of Rare EGFR Mutations in Advanced NSCLC
Lead Sponsor:
Provitro GmbH
Collaborating Sponsors:
AstraZeneca
Charite University, Berlin, Germany
Conditions:
Mutations in Exons 18 to 21
Eligibility:
All Genders
Brief Summary
While current mutational analyses comprise exons 19 and 21 in which the majority of EGFR-mutations occur, this study aims at investigating the relevance of exon 18 and 20 mutations. Therefore, the inv...
Eligibility Criteria
Inclusion
- NSCLC Stadium III-IV
Exclusion
- no NSCLC or different stadium
Key Trial Info
Start Date :
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT01215474
Last Update
June 16 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Pathology, Charité University Medicine Berlin
Berlin, Germany, 10117